entacapone


Also found in: Medical, Wikipedia.
Related to entacapone: amantadine, pramipexole, Selegiline
Translations

entacapone

n entacapona
References in periodicals archive ?
In June 2003, Orion Pharma received the Marketing Authorization from FDA for Stalevo, a new treatment of PD, which combines levodopa and carbidopa with entacapone in one tablet.
Other helpful drugs for response fluctuations include "COMT inhibitors" such as entacapone, as well as Eldepryl and amantadine.
Conversely, market growth will be constrained through 2021 by the increased uptake of generic versions of ropinirole (both immediate- and controlled-release formulations) and pramipexole (both immediate- and extended-release formulations), as well as the entrance of generic versions of other prominent Parkinson's disease agents, entacapone (Novartis/Orion Pharma's Comtan/Comtess/Stalevo, generics) and Teva/Lundbeck's Azilect/Agilect.
open-house-model" in the period from 15/04/2016 to 03/31/2018 for medicines for drug entacapone (atc code by who : n04bx02).
The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease.
Wockhardt USA's recent approvals include: clarithromycin IR tablets, fluticasone nasal spray, valacyclovir HCI caplets, carbidopa, entacapone, levodopa oral tablets and alfuzosine HCI ER tablets.
Adding a cathecol-O-methyltransferase (COMT) inhibitor, such as entacapone, to increase levodopa's effectiveness has been shown to reduce motor fluctuations (2,3,10) (SOR: B).
ASCEND-PD is a multinational Phase III comparative study of IPX066 to carbidopa-levodopa and entacapone in subjects with advanced PD.
The FDA is continuing to review the cardiovascular safety of Stalevo, a three-drug-in-one pill for Parkinson's disease, after completing a meta-analysis that failed to resolve the issue of whether adding entacapone to a carbidopa/levodopa combination increases cardiovascular risk, the agency announced last month.
An excess number of prostate cancer cases among men treated with the Parkinson's disease product that contains entacapone, carbidopa, and levodopa in a controlled clinical trial has prompted an FDA review of the combination drug's safety.
carbidopa/levodopa and entacapone previously administered as individual products and to replace immediate-release